GSK

News

Herpes simplex virus (HSV-2) capsid visualisation

GSK drops HSV jab, leaving rival mRNA shots in pole position

GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ground to mRNA shots in development at Moderna and BioNTech.

News

ERS: GSK reveals data behind new asthma hope depemokimab

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS

News

GSK says Nucala hits the target in new COPD trial

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<

News

GSK gets EU okay for RSV shot in younger age group

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could l

News

GSK bags breakthrough status for B7-H3 ADC for lung cancer

An antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion deal last year has been given breakthrough status by the FDA.

News

GSK bags sought-after Jemperli okay in endometrial cancer

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions f

GSK drops HSV jab, leaving rival mRNA shots in pole position

ERS: GSK reveals data behind new asthma hope depemokimab

GSK says Nucala hits the target in new COPD trial

GSK gets EU okay for RSV shot in younger age group

GSK bags breakthrough status for B7-H3 ADC for lung cancer

GSK bags sought-after Jemperli okay in endometrial cancer

Getting predictive technologies to patients, with Concr

Discover a new era of healthcare panel engagement: Grounded ...

GSK

Editor's Picks